|
|
SFX by Ex Libris Inc. |
Contains information about title and source of a journal
Naslov: |
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial |
Vir: |
|
|
|
|
List of services to meet your request
Contains list of services for current record
Basic services |
|
|
Več možnosti |
|
|
© 2024 SFX by Ex Libris Inc. | Piškotki
CrossRef Omogočeno
|